Shigella bacteria are the cause of shigellosis (or bacillary dysentery) which is prevalent in developing nations. Shigella vaccines aim to provide protection against shigellosis and its associated diarrhea, abdominal cramps and fever.
The global Shigella Vaccines Market is estimated to be valued at US$ 574.20 Million in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the Shigella Vaccines Market is the focus on developing affordable and effective Shigella vaccines for mass immunization programs. Low-cost vaccines are especially needed for developing nations where the disease burden is highest. Researchers are currently testing various vaccine candidates that can provide broad protective immunity against the four serogroups of Shigella. The development of such multivalent vaccines with improved efficacy and affordability could significantly boost vaccination rates and control Shigella infections globally.
SWOT Analysis
Strengths: Shigella bacterial infections are a major public health concern especially in developing countries. A vaccine represents an effective preventive measure to control disease transmission and burden.
Weaknesses: Developing a vaccine against invasive bacteria like Shigella is scientifically challenging. Efficacy may vary depending on serotype coverage. High development costs and regulatory hurdles exist.
Opportunities: Growing research focus on conjugate vaccine development against multiple serotypes opens new opportunities. Support from global health organizations to developing countries to introduce affordable vaccines.
Threats: Emergence of multi-drug resistant strains poses treatment challenges. Biosimilar competition once leading vaccines get introduced. Uncertain demand and pricing constraints in target developing country markets.
Key Takeaways
The global Shigella vaccines market is expected to witness high growth, exhibiting CAGR of 6.4% over the forecast period, due to increasing burden of Shigella infections worldwide especially in low and middle income countries with poor sanitation and hygiene conditions.
Regional analysis: The Asia Pacific region is expected to dominate the market over the forecast period, owing to large populations, low hygiene standards, and lack of preventive healthcare in several developing nations like India and Bangladesh. China, India, Pakistan, and Indonesia have the highest shigellosis disease burden globally.
Key players operating in the Shigella vaccines market are MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc. GlaxoSmithKline’s investigational conjugate vaccine is in Phase 3 testing. Other players are focusing on improving serotype coverage and developing affordable vaccines for sustainable introduction in target public health programs.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
